Epidermal growth factor receptor inhibitors in oncology

Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609

K Kuester, A Kovar, C Lüpfert, B Brockhaus, C Kloft, Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. British Journal of Cancer. ,vol. 98, pp. 900- 906 ,(2008) , 10.1038/SJ.BJC.6604265

Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne, Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Cancer Cell. ,vol. 17, pp. 77- 88 ,(2010) , 10.1016/J.CCR.2009.11.022

Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449

Daekee Lee, Ming Yu, Eunjung Lee, Hyunok Kim, Yanan Yang, Kyoungmi Kim, Christina Pannicia, Jonathan M. Kurie, David W. Threadgill, Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium Journal of Clinical Investigation. ,vol. 119, pp. 2702- 2713 ,(2009) , 10.1172/JCI36435

Lecia V. Sequist, Daphne W. Bell, Thomas J. Lynch, Daniel A. Haber, Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 25, pp. 587- 595 ,(2007) , 10.1200/JCO.2006.07.3585

A. M. Scott, F.-T. Lee, N. Tebbutt, R. Herbertson, S. S. Gill, Z. Liu, E. Skrinos, C. Murone, T. H. Saunder, B. Chappell, A. T. Papenfuss, A. M. T. Poon, W. Hopkins, F. E. Smyth, D. MacGregor, L. M. Cher, A. A. Jungbluth, G. Ritter, M. W. Brechbiel, R. Murphy, A. W. Burgess, E. W. Hoffman, T. G. Johns, L. J. Old, A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors Proceedings of the National Academy of Sciences of the United States of America. ,vol. 104, pp. 4071- 4076 ,(2007) , 10.1073/PNAS.0611693104

Fumin Shi, Shannon E. Telesco, Yingting Liu, Ravi Radhakrishnan, Mark A. Lemmon, ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proceedings of the National Academy of Sciences of the United States of America. ,vol. 107, pp. 7692- 7697 ,(2010) , 10.1073/PNAS.1002753107

, Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature. ,vol. 455, pp. 1061- 1068 ,(2008) , 10.1038/NATURE07385

N. P. Shah, D.-W. Kim, H. Kantarjian, P. Rousselot, P. E. D. Llacer, A. Enrico, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, M. C. Muller, A. Lambert, Y. Matloub, A. Hochhaus, Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib Haematologica. ,vol. 95, pp. 232- 240 ,(2010) , 10.3324/HAEMATOL.2009.011452